ReviewIntensive care medicine2017
Focus on immunocompromised patients.
Review in Intensive care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Surgical site infection prevention and management in immunocompromised patients: a systematic review of the literature.World journal of emergency surgery : WJES · 2021Pooled it
- HAMSIAA protects cyclophosphamide induced immunosuppression by modulating gut homeostasis and purine metabolism.Frontiers in immunology · 2026Article
- Development of a prediction model for in-hospital mortality in immunocompromised chronic kidney diseases patients with severe infection.BMC nephrology · 2025Article
- Nursing management of pulmonary mucormycosis with skin damage secondary to amphotericin B colloidal dispersion: a case report.Frontiers in medicine · 2025Article
- Multistate modeling for survival analysis in critically ill patients treated with meropenem.CPT: pharmacometrics & systems pharmacology · 2024Article
- A Nomogram Based on Comorbidities and Infection Location to Predict 30 Days Mortality of Immunocompromised Patients in ICU: A Retrospective Cohort Study.International journal of general medicine · 2021Article
- Impact of early therapeutic modality on 28-day mortality in immunocompromised patients with opportunistic pulmonary infections: a multicenter retrospective study.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28597035What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.